GAS5 lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells by Yacqub-Usman, Kiren et al.
  








Item type Meetings and Proceedings
Authors Yacqub-Usman, Kiren; Pickard, Mark R.; Williams, Gwyn
T.
Citation Yacqub-Usman, K., Pickard, M., & Williams, G. (2014).
GAS5 lncRNA Modulates the Action of mTOR Inhibitors
in Prostate Cancer Cells. Paper presented at the NCRI
Cancer Conference 2014.
Publisher NCRI Cancer Conference 2014 Abstracts
Downloaded 6-Nov-2017 13:48:02
Item License http://creativecommons.org/licenses/by-nc-nd/4.0/
Link to item http://hdl.handle.net/10034/614989
GASS lncRNA Modulates the Action of mTOR Inhibitors in Prostate Cancer Cells 
Kiren Yacqub-Usman, Mark Pickard & Gwyn Williams 
Keele University, Keele, Staffordshire, UK 
 
Background  
There is a need to develop new therapies for castrate-resistant prostate cancer (CRPC) and growth 
arrest-specific 5 (GAS5) long non-coding RNA (lncRNA), which riborepresses androgen receptor 
action, may offer novel opportunities in this regard. GAS5 lncRNA expression declines as prostate 
cancer cells acquire castrate-resistance, and decreased GAS5 expression attenuates the responses of 
prostate cancer cells to apoptotic stimuli. Enhancing GAS5 lncRNA expression may therefore offer a 
strategy to improve the effectiveness of chemotherapeutic agents. GAS5 is a member of the 5' 
terminal oligopyrimidine gene family, and we have therefore examined if mTOR inhibition can 
enhance cellular GAS5 levels in prostate cancer cells. In addition, we have determined if GAS5 
lncRNA itself is required for mTOR inhibitor action in prostate cancer cells, as recently demonstrated 
in lymphoid cells.  
Method  
The effects of mTOR inhibitors on GAS5 lncRNA expression and cell proliferation were determined in 
a range of prostate cancer cell lines. Transfection of cells with GAS5 siRNA and plasmid constructs 
was performed to determine the involvement of GAS5 lncRNA in mTOR inhibitor action.  
Results  
Treatment with rapamycin and rapalogues increased cellular GAS5 levels and inhibited culture 
growth in both androgen-dependent (LNCaP) and androgen-sensitive (22Rv1) cell lines, but not in 
androgen-independent (PC-3 and DU145) cells. GAS5 silencing in both LNCaP and 22Rv1 cells 
decreased their sensitivity to growth inhibition by mTOR inhibitors. Moreover, transfection of GAS5 
lncRNA sensitized PC-3 and DU145 cells to mTOR inhibitors, resulting in inhibition of culture growth.  
Conclusion  
mTOR inhibition enhances GAS5 transcript levels in some, but not all, prostate cancer cell lines. This 
may in part be related to endogenous levels of GAS5 expression, which tend to be lower in prostate 
cancer cells representative of advanced disease, particularly since current findings demonstrate a 
role for GAS5 lncRNA in mTOR inhibitor action in prostate cancer cells. 
